Influenza can cause serious complications among elderly individuals, including pneumonia and exacerbation of underlying conditions that can result in hospitalization or death [1] . With a high proportion of elderly residents who have underlying health problems and close living conditions, long-term care facilities (LTCFs) are vulnerable to outbreaks of influenza [2, 3] , and such outbreaks are often associated with considerable morbidity and mortality [3, 4] . Vaccination of residents and staff prior to the influenza season is the cornerstone of primary prevention of influenza in LTCFs [2] . Vaccination is important in reducing complications from influenza and has been shown to be 50%-60% effective in preventing hospitalization or pneumonia and 80% effective in preventing death among residents of LTCFs [5] . However, vaccination is typically only 30%-40% effective in preventing influenza in elderly persons residing in LTCFs [6] . Therefore, influenza outbreaks occur in LTCFs despite high vaccination coverage rates among residents. Once an outbreak of influenza is recognized in a LTCF, secondary prevention and control are based on: (1) heightened infection-control procedures, (2) vaccination of unvaccinated residents and staff, (3) antiviral treatment of residents and staff with influenza A, and (4) antiviral chemoprophylaxis of healthy residents and staff [3] .
The impact of secondary chemoprophylaxis, in which antiviral medication is administered after the occurrence of a case of influenza in an LTCF, has not been comprehensively studied. Several descriptive studies of single facilities in which amantadine or rimantadine chemoprophylaxis was initiated at varying times after the onset of an influenza A outbreak found a decreased influenza attack rate during the chemoprophylaxis period, compared with during the prechemoprophylaxis period [7] [8] [9] [10] [11] . There are data that support the effectiveness of oseltamivir and zanamivir, neuraminidase inhibitors that are licensed for chemoprophylaxis, in controlling outbreaks in LTCFs [12] [13] [14] [15] [16] [17] [18] [19] , including a study in which prophylaxis with zanamivir was more effective than prophylaxis with rimantidine [16] . Although some studies reported the time between the onset of the first case of influenza and/or influenza-like illness and initiation of chemoprophylaxis, none had sufficient data to determine whether prompt administration of prophylaxis with any of the 4 agents reduced the duration or severity of the outbreak [7-13, 15, 16, 18, 19] . Although there have not been randomized, placebo-controlled studies of the adamantane derivatives for secondary chemoprophylaxis of influenza A in LTCFs with elderly resident populations, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommends that chemoprophylaxis be initiated as soon as possible when a confirmed or suspected outbreak of influenza occurs in an institution with residents at high risk for infection, such as an LTCF [5] . This analysis is designed to assess the impact of timing of secondary chemoprophylaxis with amantadine on outbreaks of influenza A in multiple LTFCs over several influenza seasons. cases of influenza-like illness on a unit of an LTCF. The information requested includes facility name and address, bed capacity, date of onset of symptoms in index resident, causative agent, number of people initially ill, predominant symptoms and duration of illness, control measures taken by the facility, type of laboratory specimens collected, and type of laboratory tests performed [20] . Additional information, solicited by telephone calls by DOHMH personnel during the outbreak, included percentage of residents vaccinated against influenza, number and date of illness onset for additional residents and staff with influenza A, duration of illness, number of hospitalizations, number of deaths, total number of staff, infectioncontrol measures employed, type of antiviral chemoprophylaxis used (if any), extent of use of antiviral chemoprophylaxis (unitwide vs. facility-wide administration), time to initiation of antiviral chemoprophylaxis after onset of outbreak, and updated information regarding laboratory testing and results. LTCFs with influenza A outbreaks identified by DOHMH personnel through active laboratory surveillance were contacted by DOHMH personnel, who instructed the facilities to submit the report and solicited the aforementioned information.
METHODS

Ascertainment
Inclusion criteria. Outbreaks included in this analysis met the following criteria: (1) they occurred in a facility with an adult resident population; (2) they consisted of at least 1 laboratory-confirmed case of influenza A or у2 cases of an influenza-like illness on a unit within a facility, with subsequent laboratory confirmation of influenza A; and (3) amantadine chemoprophylaxis was administered to residents on a single unit or throughout the facility.
Definitions. Onset of an influenza A outbreak was defined as the first day on which symptoms were present in an index case that was subsequently confirmed by laboratory testing to be influenza A. Time to initiation of amantadine chemoprophylaxis was defined as the number of days between onset of an outbreak and initiation of amantadine chemoprophylaxis. Duration of outbreak was defined as the number of days between onset of symptoms in the index case and onset of symptoms in the last case. Resident incidence rate was estimated as the number of residents with influenza A divided by the total number of beds. Case-hospitalization rate was defined as the number of residents hospitalized with cases of influenza A divided by the total number of residents with influenza A. Casefatality rate was defined as the number of deaths due to influenza divided by the total number of residents with influenza A. Time between initiation of chemoprophylaxis and the end of an outbreak was defined as the time interval in days between the initiation of chemoprophylaxis and the onset of symptoms in the last case in an outbreak. Influenza season year was defined as the season year in which the outbreak occurred (2001-2002, 2002-2003, or 2003-2004) . Facility bed capacity was defined as the total number of beds in a facility when at maximum capacity. Proportion of residents vaccinated against influenza was defined as the number of residents who received the influenza vaccine divided by the facility bed capacity. Statistical methods. We examined whether mean duration of outbreaks, incidence rates, case-fatality rates, hospitalization rates, and other factors differed according to whether facilities initiated chemoprophylaxis р5 days or 15 days after outbreak onset using Student's t tests for continuous data and x 2 tests for categorical data. Time between outbreak onset and initiation of chemoprophylaxis was dichotomized at 5 days, because that was the median number of days between outbreak onset and the initiation of chemoprophylaxis in our sample. Another reason that this cutoff value was chosen was because it seems to be clinically reasonable to recognize that a resident may have influenza, obtain specimens and send them to the laboratory, obtain the laboratory results, and initiate treatment and chemoprophylaxis within a 5-day period. We evaluated these associations-controlling for factors that have been shown to be important in previous studies (such as influenza season year, facility bed capacity, and proportion of residents vaccinated against influenza)-using multivariate analysis of covariance. Facility bed capacity and proportion of residents vaccinated against influenza were treated as continuous variables. We determined the incremental effect of each additional day of delayed initiation of chemoprophylaxis controlling for the same potential confounders and using linear regression, after ensuring that the assumptions for linear regression were met. Outliers in the data set were examined by looking at Cook's distance, a measure of influence of a case in the regression equation. Fox's recommendation of using a cutoff value for detecting influential cases-values of , where n is the D 1 4/(n Ϫ k Ϫ 1) number of cases and k is the number of predictor variableswas used to determine if any outliers were significantly influencing the regression equation [21] . All statistical analyses were conducted using SPSS, version 14.0 (SPSS). . Amantadine chemoprophylaxis was initiated in 56 of these outbreaks, and data were sufficiently complete for analysis in 52 (93%). Amantadine chemoprophylaxis was initiated facility-wide in 40 (77%) of the outbreaks and was limited to the affected unit in the remaining 16 outbreaks. The time between onset of influenza A outbreak and initiation of chemoprophylaxis ranged from 0 to 34 days (median duration, 5 days; figure 1).
RESULTS
Over
Chemoprophylaxis was initiated within 5 days after outbreak onset in 27 (52%) of the outbreaks analyzed (table 1). The 3 influenza season years did not differ in a statistically significant way with respect to the percentage of outbreaks reported in which chemoprophylaxis was initiated р5 days or 15 days after outbreak onset ( ). Chemoprophylaxis was adminis-P p .913 tered facility-wide in 21 (78%) of the outbreaks in which chemoprophylaxis was initiated р5 days after outbreak onset and in 19 (76%) of the outbreaks in which chemoprophylaxis was initiated 15 days after outbreak onset ( ). In the re-P p .897 maining outbreaks, chemoprophylaxis was administered only to residents on the affected unit (6 [22%] of the outbreaks in which chemoprophylaxis was initiated р5 days after outbreak onset and 6 [24%] of the outbreaks in which chemoprophylaxis was initiated 15 days after outbreak onset).
Initiation of chemoprophylaxis 15 days after the onset of outbreaks was associated with statistically significantly longer duration of outbreaks, higher incidence rates, and higher casefatality rates (table 1). The duration of outbreaks was statistically significantly longer in facilities that initiated chemoprophylaxis 15 days after outbreak onset, compared with the duration of outbreaks in facilities that initiated chemoprophylaxis р5 days after outbreak onset (18.3 vs. 6.7 days; ), P ! .001 adjusting for influenza season year, facility bed capacity, and proportion of residents vaccinated against influenza (table 2). Mean incidence rate was statistically significantly higher in facilities that initiated chemoprophylaxis 15 days after the onset of outbreaks, compared with the mean incidence rate in facilities that initiated chemoprophylaxis р5 days after outbreak onset (10.5 vs. 6.2 cases per 100 residents; ), adjusting P ! .023 for the same factors (table 2) . Case-fatality rate was statistically significantly higher in facilities in which chemoprophylaxis was initiated 15 days after the onset of outbreaks, compared with case-fatality rates in facilities that initiated chemoprophylaxis р5 days after outbreak onset (3.3 vs. 0.5 deaths per 100 residents with influenza A; ), adjusting for the same factors P ! .005 (table 2) . We tested this hypothesis after examining whether any outliers were significantly influencing the regression equation. Four observations met Fox's criterion (in this case, D values 1.085) for influential cases. After deleting these 4 observations, the regression analysis was rerun, resulting in no meaningful changes in the significance of differences, compared with the findings when the 4 cases were included.
Using linear regression, adjusting for influenza season year, facility bed capacity, and proportion of residents vaccinated against influenza (table 3), for each day that the initiation of chemoprophylaxis was delayed after outbreak onset, outbreaks lasted 1.3 days longer ( ). P ! .001
DISCUSSION
To our knowledge, this is the first large study to examine the effect of timing of antiviral chemoprophylaxis with amantadine on the severity and duration of outbreaks of influenza A in LTCFs over multiple influenza seasons. LTCFs that initiated amantadine chemoprophylaxis 15 days after the onset of an outbreak of influenza A had significantly longer duration of outbreaks, higher incidence rates, and higher case-fatality rates than did facilities that initiated chemoprophylaxis р5 days after outbreak onset. For each day that initiation of chemoprophylaxis was delayed, outbreaks lasted 11 additional day. Further analyses are necessary to determine whether incidence and casefatality rates are decreased with each earlier day of chemoprophylaxis initiation. Because we could not recommend nontreatment to LTCFs, we could not evaluate the effectiveness of amantadine chemoprophylaxis versus nontreatment.
There are several limitations to this study. In addition to timing of amantadine chemoprophylaxis, other factors that were not available for analysis may have affected the outcomes studied. These additional potential confounders include time- liness of initiation of infection-control measures, proportion of LTCF staff vaccinated against influenza, secondary vaccination or chemoprophylaxis of unvaccinated residents and staff during outbreaks, the proportion of residents receiving secondary prophylaxis, and demographic characteristics of LTCF residents. In addition, because ascertainment of outbreaks consisted primarily of passive reports and limited laboratory-based active surveillance, it is likely that not all outbreaks of influenza A in New York City LTCFs were identified, potentially resulting in an ascertainment bias. Although the number of outbreaks identified varied by influenza season year, this is less likely to represent underreporting than it is to reflect the severity of the influenza seasons. Interestingly, the number of outbreaks identified in LTCFs in New York City during the study seasons mirrored the overall severity of the influenza seasons nationally in the United States [22] [23] [24] .
Further, because data on the bed occupancy at each LTCF at the time of an outbreak was not available, we used the maximum occupancy of each LTCF as the denominator in incidence rate calculations. Therefore, it is possible that we underestimated the true incidence rates. However, there is no reason to believe that any potential underestimate differed according to the timing of initiation of antiviral chemoprophylaxis during outbreaks. Finally, it is important to note that the outbreaks analyzed occurred before widespread adamantane resistance was found in circulating influenza strains [25] . Also, data on the adverse effects of amantadine use were not systematically collected. This analysis is limited to the use of amantadine chemoprophylaxis, because neuraminidase inhibitors were infrequently used for treatment and prevention of influenza A in LTCFs in New York City during this period.
If earlier administration of chemoprophylaxis with amantadine decreases the severity of outbreaks of influenza A, strategies are needed to increase the speed of initiation of chemoprophylaxis. For facilities, such strategies could include the following: a high index of suspicion for cases; maintenance of a low threshold for obtaining specimens for influenza infection detection; rapid transportation of specimens to laboratories; use of rapid testing with culture confirmation or onsite testing with subsequent laboratory confirmation; efficient communication of laboratory results to LTCFs; pre-established criteria for defining an outbreak and for initiation of antiviral medication; and prescreening of residents for prescribing of amantadine, along with routine influenza vaccination. Health departments can play an important role in facilitating the implementation of these strategies. For example, they could increase the frequency with which influenza outbreaks are reported by promoting influenza awareness. Beginning in October, health departments could remind infection control practitioners, nursing leadership, and medical directors of LTCFs that residents with cold-like or febrile illness should be tested for influenza. Health departments also could increase ascertainment and minimize time to initiation of antiviral chemoprophylaxis by requiring laboratories to report positive influenza laboratory results from LTCF residents by telephone to personnel at LTCFs and appropriate health departments. In addition, electronic outbreak reporting from LTCFs could enable health departments to provide timely infection control and chemoprophylaxis recommendations to LTCFs at the first indications of an outbreak.
We found that, in LTCFs where chemoprophylaxis was initiated 15 days after the onset of influenza A outbreaks during influenza seasons for the period 2001-2004, there were statistically significantly longer outbreaks, higher incidence rates, and higher case-fatality rates, compared with those in LTCFs where chemoprophylaxis was started sooner. When adamantine resistance is not widespread in circulating influenza strains, these data support prompt initiation of amantadine chemoprophylaxis after identification of influenza A in LTCFs.
